论文部分内容阅读
目的观察尤瑞克林联合阿替普酶静脉溶栓治疗超急性期脑梗死的临床效果。方法选取医院神经内科收治的急性脑梗死患者160例为研究对象,随机分为观察组和对照组,每组80例。对照组采用尤瑞克林治疗,观察组采用尤瑞克林联合阿替普酶治疗。观察2组临床治疗效果、神经功能缺损评分(NHISS和CSS)和日常生活能力评分(BI)情况。结果 2组患者在接受各组针对性治疗1、7、14 d后,神经功能和生活能力评分均得以改善,治疗时间越长,效果越显著(P均<0.05);治疗时间达到14 d,观察组NHISS、CSS和BI评分优于对照组(P<0.05)。观察组总有效率为95.00%,高于对照组的77.50%(P<0.05)。结论尤瑞克林联合阿替普酶静脉溶栓治疗超急性期脑梗死患者疗效显著,患者神经功能恢复快,接受度高,且安全性强,值得临床推广应用。
Objective To observe the clinical effect of intravenous thrombolytic therapy combined with ereclidine in the treatment of hyperacute cerebral infarction. Methods A total of 160 acute cerebral infarction patients admitted to Department of Neurology were selected as the research object and randomly divided into observation group and control group, 80 cases in each group. The control group was treated with uracil and the observation group was treated with uracil and alteplase. The clinical curative effect, neurological deficit score (NHISS and CSS) and daily living ability score (BI) were observed in two groups. Results After 2, 7 and 14 days of targeted therapy, the scores of neurological function and viability were improved in both groups. The longer the treatment was, the more obvious the effect was (P <0.05). The treatment time reached 14 days, The scores of NHISS, CSS and BI in the observation group were better than those in the control group (P <0.05). The total effective rate in the observation group was 95.00%, which was higher than that in the control group (77.50%, P <0.05). Conclusion The combination of intravenous thrombolysis with eptifibatide and altreplase in the treatment of patients with hyperacute cerebral infarction has significant curative effect, rapid recovery of neurological function, high acceptability and high safety. It is worthy of clinical application.